ContraFect’s Path Forward Gets Murky With Exebacase Trial Failure

 
• By Alaric DeArment
  
ContraFect said it stopped its Phase III trial of exebacase in MRSA for futility • Source: Shutterstock

More from Clinical Trials

More from R&D